Focusing on the CROWN study, Faith Abodunrin, MD, discusses the role of lorlatinib in the treatment of patients with non–small cell lung cancer.
The Role of Artificial Intelligence in Enhancing Precision Medicine for NSCLC
AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.
Practice-Changing Lung Cancer Data From The 2025 ASCO Annual Meeting
Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.
Dato-DXd Earns FDA Accelerated Approval in Pretreated EGFR-Mutated mNSCLC
The decision is supported by results from the phase 2 TROPION-Lung05 and phase 3 TROPION-Lung01 trials.
Adopting Best Practices for Administering TROP2-Directed ADCs in NSCLC
Experts from Washington University in St Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.
FDA Approves Taletrectinib in ROS1+ NSCLC
Supporting results for the approval of taletrectinib in ROS1+ NSCLC come from the TRUST-I and TRUST-II trials.
Sacituzumab Tirumotecan Enhances Efficacy in Pretreated EGFR-Mutant NSCLC
Sacituzumab tirumotecan showed a manageable safety profile compared to docetaxel in patients with EGFR-mutant advanced non–small cell lung cancer.